Food allergy is an adverse reaction due to a specific immune response
occurring reproducibly upon exposure to certain foods. It occurs minutes
to hours after food consumption.
Immunological mechanisms can be IgE mediated, non-IgE mediated or mixed IgE and non-IgE mediated.
It may be life-threatening and is the most common cause of anaphylaxis in children.
It should be differentiated from food intolerance in which adverse
reactions from exposure to food arise from non-immunological mechanisms.
Children and adolescents with severe peanut allergy treated with the peanut-derived oral biologic immunotherapy drug AR101 may improve their tolerance to peanut protein with reduced symptom severity, according to the phase III PALISADE* trial.
Exclusive breastfeeding for 6 months is advisable for allergy prevention, while hydrolyzed formulas (HFs) with reduced allergenicity may be considered for mothers who are unable or choose not to breastfeed, an expert recommended.
Combining an initial 16-week course of the monoclonal antibody omalizumab with oral immunotherapy (OIT) significantly and safely improves desensitization to the offending foods compared with OIT alone in children and adolescents with multiple food allergies, a new study found.
The presence of eczema or atopic dermatitis with concurrent allergic sensitization at 1 year of age was associated with an increased risk of developing asthma and food allergy in later childhood at 3 years old, according to the CHILD* study.
High free sugar intake during pregnancy was associated with a heightened risk of allergy and allergic asthma in the children, independent of their sugar intake during early childhood, according to the ALSPAC* study.
Delivery of peanut protein through the skin by means of a wearable skin patch, an approach known as epicutaneous immunotherapy, is safe and shows promise for treating peanut allergy, especially in young children, according to interim results of an ongoing study.
Acquired immunodeficiency syndrome (AIDS) remains as one of the world’s leading causes of mortality in global public health. Dr Charles Hicks shared his insights into the increasing role of dolutegravir (DTG; Tivicay, GSK) – an integrase strand transfer inhibitor (INSTI) – in HIV therapy during the 4th National AIDS Conference 2018 at Swiss Garden International Hotel and Residences, Kuala Lumpur.
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Long-term treatment with the interleukin-5
receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.